Neonc Technologies Holdings, Inc. · NASDAQ:NTHI
Neonc Technologies — Investor Presentation (March 2026)
22 slides from Neonc Technologies's investor presentation, Mar 6, 2026
Slide 1: Removing Barriers to Effective Neuro-Drug Delivery Corporate Presentation 2026
Removing Barriers to Effective Neuro - Drug Delivery Corporate Presentation 202 6 NT HI Phase 1/2 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH - mutant, Glioblastoma IDH - wildtype or Brain Metastasis (NCT06047379)
Slide 2: Important Cautions Regarding Forward Looking Statements
Important Cautions Regarding Forward Looking Statements © NeOnc Technologies Holdings, Inc. 2022 - 2025. All Rights Reserved. Proprietary. 2 This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities. The distribution may be restrict
Slide 3: Senior Management Team, Board of Directors, Scientific Advisory Board
Senior Management Team Board of Directors Scientific Advisory Board
Slide 4: Phase Development & Clinical Pipeline
Phase 2 Development & Clinical Pipeline 4 FDA Authorized Clinical Trials Commercialization Phase III Phase II Phase I IND Enabling * Preclinical Indication Application Drug Candidate Recurrent Grade III & Grade IV Astrocytoma Brain Cancer w/ IDH1 Mutation Intranasal NEO100 NEO100 - 01 Meningioma Bra
Slide 5: GBM & Temozolomide (TMZ): Fundamental Limitations
5 GBM & Temozolomide (TMZ): Fundamental Limitations Bottom line: Temozolomide validated market demand in GBM; its clinical limitations inform the development rationale for NEO212 2nd - Line Recurrent Brain Tumor Benchmarks • Foundational standard of care since ~2005 , used with surgery and radiation
Slide 6: NEO212: Brain-Optimized Temozolomide Bioconjugate Designed to Enhance Brain Tumor Targeting
NEO212: Brain - Optimized Temozolomide Bioconjugate Designed to Enhance Brain Tumor Targeting NEO100 Temozolomide (TMZ) Carbamide Bond NEO212 Bioconjugated Molecule 6 Novel bioconjugate combining NEO 100 with temozolomide (TMZ) . Builds on TMZ, the established GBM standard of care, with the goal of
Slide 7: NEO212 Degrades MGMT and Overcomes TMZ Resistance in GBM
7 NEO212 Degrades MGMT and Overcomes TMZ Resistance in GBM Chen TC et al. Cancer Lett. 2015 Mar 28;358(2):144 - 151. Cho HY et al. Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. Cho HY et al Mol Cancer Ther. 2014 Aug;13(8):2004 - 17. NEO212 Achieves Higher Intratumoral TMZ/AIC Exposure in TMZ - Resistant
Slide 8: NEO212 Demonstrates Enhanced Brain Delivery and Antitumor Activity in TMZ-Resistant GBM
8 NEO212 Demonstrates Enhanced Brain Delivery and Antitumor Activity in TMZ - Resistant GBM BBB penetration ↑ | Overall survival ↑ | Tumor size ↓ Chen TC et al. Cancer Lett. 2015 Mar 28;358(2):144 - 151. Cho HY et al. Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. Cho HY et al Mol Cancer Ther. 2014 Aug;1
Slide 9: NEO212 Mechanism of Action
NEO212 Mechanism of Action 9 Chen TC et al. Cancer Lett. 2015 Mar 28;358(2):144 - 151. Cho HY et al. Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. Cho HY et al Mol Cancer Ther. 2014 Aug;13(8):2004 - 17.
Slide 10: NEO212: Novel Alkylating Therapy in Clinical Development for Brain Tumors
NEO212: Novel Alkylating Therapy with Preclinical Evidence of MGMT Inactivation and Brain Penetration in Clinical Development for Brain Tumors 10 Broad Scope: Primary brain tumors and brain metastases as monotherapy and in combination with SOC Differentiation vs TMZ: Up to 10 î greater preclinical e
Slide 11: Phase 1: Safety and Efficacy of NEO212 in Astrocytoma, GBM or Brain Metastasis
Phase 1: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH - mutant, Glioblastoma IDH - wildtype or Brain Metastasis Phase 1: (dose escalation) Primary Objectives : • Assess the safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astroc
Slide 12: Low Peripheral Blood Detection of NEO212 Metabolites in Phase 1 PK Samples
12 Low Peripheral Blood Detection of NEO212 Metabolites (AIC and PA) in Phase 1 PK Samples, Consistent with Preclinical Observations of Tumor Uptake and Intratumoral Metabolism Cohort 5 (810 mg/QD) Cohort 4 (610 mg/QD) Cohort 3 (400 mg/QD) Cohort 2 (220 mg/QD) Cohort 1 (170 mg/QD) 2 3 3 3 3 N (evalu
Slide 13: Lower AIC Levels Observed with NEO212 vs Temozolomide
13 39 î Lower AIC Levels Observed with NEO212 vs Temozolomide, Reflecting Reduced Systemic Metabolite Levels and Potentially Supporting an Improved Hematologic Safety Profile Fig . 4 Representative TMZ ( F ), MTIC ( E ), and AIC ( Ƒ ) concentra - tion - time profiles from a patient who received 200
Slide 14: NEO212 PK: No Clinically Meaningful Myelosuppression Detected
NEO212 PK: No Clinically Meaningful Myelosuppression Detected
Slide 15: NEO212 PK: No Clinically Meaningful Hepatic or Renal/Urinary Toxicity Observed
NEO212 PK: No Clinically Meaningful Hepatic or Renal/Urinary Toxicity Observed
Slide 16: MTD Cohort (810 mg QD) – Key Learnings
16 MTD Cohort 5 (810 mg QD) – Key Learnings Observed SAEs were consistent with complications commonly seen in advanced recurrent GBM and during temozolomide - Phase 1 dose escalation studies. Importantly, across Phase 1: • No signal of clinically meaningful myelosuppression • No hepatic or renal tox
Slide 17: NEO212 Measurable Anti-Tumor Activity in Phase 1
17 NEO212 measurable anti - tumor activity in Phase 1
Slide 18: Partial Response Observed in Recurrent IDH1 Wild-Type, MGMT-Methylated GBM
18 Partial Response Observed in Recurrent IDH1 Wild - Type, MGMT - Methylated GBM – Patient Remains Stable 21 Months Post - Recurrence Screen Cycle 21 Contrast FLAIR Primary Diagnosis: 8/25/2023 Prior Tx: XRT+TMZ (10/23 - 4/24) Progressed on TMZ After 6 Cycles NEO212 C1D1: 6/10/2024 Currently on Cyc
Slide 19: Lung-to-Brain Metastasis
19 Lung - to - Brain Metastasis | 55 Months Since Diagnosis | Last 16 Months on NEO212 Screen Cycle 7 Contrast FLAIR Brain Met Diagnosis: Squamous NSCLC (7/20/2021) Prior Tx: Taxol/Carboplatin (7/2018); Keytruda, Alimta (5/2020) NEO212 C1D1: 3/25/2024 Currently on Cycle 16
Slide 20: NEO212 — Next Potential Steps & Accelerated Regulatory Approval
20 NEO212 — Next Potential Steps & Accelerated Regulatory Approval Phase I Readout: Initial safety, PK, and preliminary efficacy data Accelerated Approval Strategy: Advancement into Two Phase II Clinical Trials •Trial 1: Randomized evaluation of single - agent NEO212 in recurrent GBM versus standard
Slide 21: NEO212: Phase 1 Clinical Data Informing an Accelerated Phase 2 Development Strategy
NEO212: Phase 1 Clinical Data Informing an Accelerated Phase 2 Development Strategy in TMZ - Resistant Glioblastoma and Brain Metastases 1. Safety Foundation Established • Phase 1 demonstrated favorable systemic tolerability Why It Matters: Temozolomide’s dose ceiling is bone marrow suppression. NEO
Slide 22: The Future of Drug Delivery – Company Contact
THE FUTURE OF DRUG DELIVERY Company Contact NeOnc Technologies Holdings, Inc. 23975 Park Sorrento , Suite 205 Calabasas, CA 91302 Tel +1 (818) 470 - NTHI Info@neonc.com www.neonc.com Investor Relations Hayden IR 2369 Lexington Avenue , Second Floor New York, New York 10017 Brett Maas Managing Partne
NeOnc Technologies Holdings — Investor Presentation (March 2026) on 6ix